Longitudinally cultured precision cut lung slices as a predictive ex vivo model for lung cancer
“By providing a reliable, ethical, and efficient alternative for lung cancer studies, PCLS could significantly enhance preclinical research and drug development, marking a critical step towards more humane and representative scientific investigations.”
South Florida’s Hispanic communities see fewer late-stage lung cancer diagnoses
“When it comes to cancer disparities, community may count. A study published Aug. 21 in the Journal of the National Cancer Institute showed that although Hispanic non-small cell lung cancer patients tend to be diagnosed at later stages than white patients, that disadvantage disappears in South Florida.”
TruSight Oncology Test Receives FDA Approval for NTRK and RET Fusion Cancers
“The TruSight Oncology (TSO) Comprehensive test has received approval from the FDA as a companion diagnostic (CDx) for 2 important cancer indications. The test is approved to identify patients with solid tumors harboring NTRK gene fusions and non–small cell lung cancer (NSCLC) harboring RET gene fusions. This marks the first distributable comprehensive genomic profiling in vitro diagnostic kit with pancancer companion diagnostic claims to be approved by the FDA.”
Merck Provides Update on Phase 3 KEYNOTE-867 and KEYNOTE-630 Trials
“RAHWAY, N.J.–(BUSINESS WIRE)– Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today provided updates on two Phase 3 trials, KEYNOTE-867 and KEYNOTE-630. Merck is discontinuing the Phase 3 KEYNOTE-867 trial evaluating KEYTRUDA ® (pembrolizumab), Merck’s anti-PD-1 therapy, in combination with stereotactic body radiotherapy (SBRT) for the treatment of patients with stage I or II (stage IIB N0, M0) non-small cell lung cancer (NSCLC), including those who are medically inoperable or have refused surgery. This decision is based on the recommendation of an independent Data Monitoring Committee (DMC), which reviewed data from a planned interim analysis.”
Median Technologies Announces Pivotal REALITY Study of Its eyonis™ LCS Lung Cancer Diagnostic Met All Primary and Secondary Endpoints
“eyonis™ LCS met the primary endpoint for accuracy, achieving an Area Under the Curve (AUC)1 of 0.90, significantly above the 0.80 set for regulatory clearance. eyonis™ LCS met all 9 secondary endpoints in REALITY with statistical significance.”
FDA Approves Chemo-Free Combo for Advanced Lung Cancer
“On August 29, the Food and Drug Administration (FDA) approved Rybrevant (amivantamab) plus Lazcluze (lazertinib) as a chemotherapy-free initial regimen for people with locally advanced or metastatic non-small cell lung cancer (NSCLC) with specific mutations.”
Addressing Rising Rates of Second Primary Lung Cancers
“Although early detection of lung cancer through increased screening has improved survival rates, it has created new challenges. As more patients survive, there is an increased risk of developing secondary cancers. Authors of a study published in the Journal of Thoracic Oncology discuss the surveillance, diagnosis, and management challenges of second primary lung cancer (SPLC), noting that its incidence may be higher than previously thought, with up to 1 in 6 survivors developing SPLC within 5 years.”
Long-term conditions could delay lung cancer diagnosis, new study finds
“A new study from researchers at Brighton and Sussex Medical School (BSMS) reveals that patients living with certain long-term health conditions may face delays in being diagnosed with lung cancer. This is particularly concerning as lung cancer remains the leading cause of cancer-related deaths in the UK for both men and women, with high mortality rates largely due to late-stage diagnosis.”
How Family History of Cancer Affects Lung Cancer Risk
“Family history of cancer is a risk factor and predictor of who may develop lung cancer, and when, according to recent study findings. The study, which was published in Lung Cancer, used data from the Thoracic Tumors Registry, a nationwide database sponsored by the Spanish Lung Cancer Group, to perform 2 analyses using artificial intelligence (AI).”
A real world analysis of secondary BRAF variations after targeted therapy resistance in driver gene positive NSCLC
“Secondary BRAF variations have been identified as a mechanism of resistance to tyrosine kinase inhibitors (TKIs) in patients with driver gene-positive NSCLC. Nevertheless, there is still a lack of consensus regarding the characteristics and subsequent treatment strategies for these patients.”
Video:
Dr Singhi on Areas of Interest in Metastatic Lung Cancer Research
